Upcoming Presentations and Webinars

Our experts attend and participate in scientific, clinical and business meetings around the world. To learn more about an upcoming event or to schedule a meeting, info@evidera.com.

  • Upcoming Webinars


    Social Media: A Rich Data Source or a Can of Worms?

    Presenters: Andrew Paul Cox, PhD, Research Scientist, Real-World Evidence, Evidera
    Wednesday, September 13 2017, 10:00 AM ET

    Registration Link


    PASS Lessons Learned - Insights on Multinational Studies

    Presenters: Javier Cid, MD, DrPH, Research Scientist, Real-World Evidence, Evidera; Beth Nordstrom, PhD, MPH, Senior Research Scientist, Real-World Evidence and Executive Director of Center of Excellence for Epidemiology, Evidera
    Thursday, September 21 2017, 10:00 AM ET

    Registration Link


    Hot Topics for Risk Evaluation and Mitigation Strategy (REMS) Programs

    Presenters: Kristin Veley, PharmD, MPH, Research Scientist and Director, REMS and Pregnancy Registries, Evidera; Sheila Weiss, PhD, FISPE, Senior Research Leader, Drug Safety, Evidera; Robin Kinard, Senior Director, Risk Management Programs, PPD
    Wednesday, October 04 2017, 10:00 AM ET

    Registration link


    Post-Authorization Safety Studies (PASS) for the Evaluation of Risk Minimization in the EU

    Presenters: Annalisa Rubino, PhD, Senior Research Scientist, Real-World Evidence, Evidera
    Wednesday, October 18 2017, 10:00 AM ET

    Registration Link

  • Upcoming Presentations

    • August 26 - 30, 2017
      Montreal, Quebec, Canada


      Beyond Retrospective Studies, Using Electronic Health Records for Prospective Research

      Authors/Presenters: Koro CE, Weiss S, Curtis L, Hernandez-Diaz S, Davis KJ, Raine J

      Pre-Conference Course

      Comparative Effectiveness Research, Database Utilization Workshop

      Authors/Presenters: Reynolds MW


      Incidence and Prevalence of Diabetes Mellitus among Children Aged 10-18 Years in the United States (US)

      Authors/Presenters: Teltsch DY, Farsani SF, Huse S, Sicignano N, Brodovicz KG, Cristaldi C, Nordstrom BL


      Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Longitudinal Assessment of Severity, Progression, and Risk Factors

      Authors/Presenters: Nordstrom BL, Simeone JC, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Bae J


      Post-Authorisation Safety Study of Pioglitazone Use in Denmark Post Label Change

      Authors/Presenters: Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V


      REMS Survey Response Rate by Stakeholder Type, Mode of Invitation Delivery, and Method of Completion

      Authors/Presenters: Veley K, Covington D, Sites S, Kinard R


      Survey of Physician-Mothers Facebook Group to Inform Pregnancy Registry Recruitment

      Authors/Presenters: Covington D, Veley K, Sites S, McKain L


      Zika Virus: Implications for Pregnancy Exposure Registries

      Authors/Presenters: Covington D, Buus R

      Oral Presentation

      Study of Mirabegron and Cardiovascular Outcomes using the Publicly Available Mini-Sentinel Protocol

      Authors/Presenters: Simeone JC, Nordstrom BL, Appenteng K, Huse S, D'Silva M

    • September 7 - 10, 2017
      Vancouver, BC, Canada


      Characteristics of Patients Newly Initiating a Preventive Treatment for Migraine: Baseline Data from the Assessment of TolerabiliTy and Effectivenss in MigrAINeurs Using Preventive Treatment (ATTAIN) Study

      Authors/Presenters: Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Mutebi A, Wilcox TK, Tepper SJ, Dodick DW, Lipton RB


      Reducing Impaired Days: Results from the STRIVE Trial, A Phase 3, Randomized, Double-Blind Study of Erenumab for Episodic Migraine

      Authors/Presenters: Hareendran A, Buse DC, Lipton RB, Bayliss MS, Mikol DD, Revicki DA, Zhang F, Desai P, Picard H, Kawata AK


      Reducing the Impact of Migraine on Functioning: Results from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine

      Authors/Presenters: Buse DC, Lipton RB, Mikol DD, Thach AV, Desai P, Picard H, Kubo Y, Hareendran A, Kawata AK

    • September 13 - 17, 2017
      Geneva, Switzerland

      Oral Presentation

      Patient Perspectives on Symptoms of Genital vs. Non-Genital Psoriasis: A Qualitative Study

      Authors/Presenters: Meeuwis K, Ryan C, Bleakman AP, Naegeli A, Poon JL, Heredia EE, Jones CA, Cather JC


      Content Validity Assessment of the Psoriasis Symptom Scale for use in Patients with Moderate to Severe Psoriasis

      Authors/Presenters: Naegeli A, Poon JL, Anatchkova M, Heredia E, Burge R

    • September 13 - 15, 2017
      Mendoza, Argentina

      Podium Presentation

      The Burden and Impact of Moderate-to-Severe Genital Psoriasis on Female Patients

      Authors/Presenters: Cather J, Potts Bleakman A, Ryan C, Poon JL, Malatestinic B, Naegeli A, Fretzin S

    • September 15 - 17, 2017
      Sao Paulo, Brazil

      Short Course

      Modelación Aplicada (Applied Modeling)

      Authors/Presenters: Caro JJ

      Issue Panel

      Health Technology Assessments (HTA) and International Reference Pricing (IRP) - How's Pharma Preparing Themselves to Optimize Evidence and the Value of their Innovation?

      Authors/Presenters: de Bustamante MM, Caro JJ, Cristancho RA, Guarin DF

      Issue Panel

      Multi-Criteria Decision Analysis (MCDA) in Latin America

      Authors/Presenters: Valentim J, Garau M, Caro JJ, Murta Amaral L

    • October 4 - 8, 2017
      San Diego, CA, USA

      Oral Presentation

      Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?

      Authors/Presenters: Lodise T, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Bonine NG


      Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?

      Authors/Presenters: Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T


      Evaluating Symptom Severity of Influenza Viral Infection Using the Influenza Patient-reported Outcomes Instrument (FLU-PRO) in a Healthy Human Challenge Model

      Authors/Presenters: Han A, Poon JL, Powers JH, Yu R, Leidy NK, Memoli M

    • October 11 - 14, 2017
      Philadelphia, PA, USA


      The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy (VVA): A Systematic Review

      Authors/Presenters: Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A

    • October 11 - 12, 2017
      London, UK


      Risk Minimization Measures: From Regulatory Framework to Practice

      Authors/Presenters: Rubino A

    • October 18 - 21, 2017
      Philadelphia, PA, USA

      Oral Presentation

      Identification of COPD Severity Phenotypes and their Relationship to Symptom-defined Exacerbation Recovery: A Latent Class Analysis

      Authors/Presenters: Murray LT

    • October 22 - 25, 2017
      Pittsburgh, PA, USA

      Short Course

      DICE Simulation for Health Care Decision-Analytic Modeling

      Authors/Presenters: Caro JJ, Moller J

    • October 31 - November 4, 2017
      Venice, Italy


      Caregiver Burden Associated with Extremely Preterm Birth

      Authors/Presenters: Sarda S, Lenderking W, Pokrzywinski R, Stringer S, Mangili A

    • November 1 - 4, 2017
      Boston, MA, USA


      Validating Trial Power in Presence of Non-Random Dropouts Using Disease Simulation

      Authors/Presenters: Tafazzoli A, Quon PL, Stern S, Kansal A

Back to Top